Literature DB >> 2785711

IgG autoantibodies against interleukin 1 alpha in sera of normal individuals.

M Svenson1, L K Poulsen, A Fomsgaard, K Bendtzen.   

Abstract

A pool of human sera from healthy blood donors was found to interfere competitively with the binding of 125I-labelled human recombinant interleukin 1 alpha (rIL-1 alpha) to the murine T-cell line EL4. The interference was reversible at the cellular level, and direct binding of the ligand to serum factors was therefore investigated. After preincubation of [125I]rIL-1 alpha with pooled serum, the 125I activity eluted in two peaks from a Sephadex G-75 column. The first was located in the void volume. The second eluted together with monomer rIL-1 alpha. An almost complete displacement of the high molecular weight 125I fraction was achieved with an excess of unlabelled rIL-1 alpha but not with rIL-1 beta. The serum factors binding to [125I]rIL-1 alpha were located in the molecular weight range 100,000-200,000, judged by fractionation on a Sephacryl S-400 column, and the factors were bound to immobilized protein A. Furthermore, [125I]rIL-1 alpha preincubated with serum co-precipitated with a specific rabbit anti-human IgG antibody. Screening of 29 sera from normal individuals showed similar effects in three cases. We conclude that approximately 10% of normal human sera contains detectable IgG autoantibodies to IL-1 alpha.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785711     DOI: 10.1111/j.1365-3083.1989.tb01149.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  23 in total

1.  Anti-interleukin 1alpha autoantibodies.

Authors:  P Miossec
Journal:  Ann Rheum Dis       Date:  2002-07       Impact factor: 19.103

2.  Inhibitor of interleukin-1 alpha and interleukin-1 beta-induced T-cell activation in serum of patients with active Crohn's disease.

Authors:  J Brynskov; M B Hansen; C Reimert; K Bendtzen
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

3.  Anti-cytokine autoantibodies in autoimmune diseases.

Authors:  Giuseppe Cappellano; Elisabetta Orilieri; Abiy D Woldetsadik; Elena Boggio; Maria F Soluri; Cristoforo Comi; Daniele Sblattero; Annalisa Chiocchetti; Umberto Dianzani
Journal:  Am J Clin Exp Immunol       Date:  2012-11-15

4.  Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors.

Authors:  C Ross; M B Hansen; T Schyberg; K Berg
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

5.  Increased incidence of neutralizing autoantibodies against interleukin-1 alpha (IL-1 alpha) in nondestructive chronic polyarthritis.

Authors:  P Jouvenne; F Fossiez; P Garrone; O Djossou; J Banchereau; P Miossec
Journal:  J Clin Immunol       Date:  1996-09       Impact factor: 8.317

Review 6.  Cytokines as mediators in the regulation of the hypothalamic-pituitary-adrenocortical function.

Authors:  J Fukata; H Imura; K Nakao
Journal:  J Endocrinol Invest       Date:  1994-02       Impact factor: 4.256

7.  Levels of gamma interferon and interleukin-4 are inversely related to the levels of their corresponding autoantibodies in patients with lower respiratory tract infection.

Authors:  R ElKarim; C Granert; L Lindquist; H Link; M Bakhiet
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

8.  Binding of cytokines to pharmaceutically prepared human immunoglobulin.

Authors:  M Svenson; M B Hansen; K Bendtzen
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

9.  Prognostic laboratory markers of joint damage in rheumatoid arthritis.

Authors:  E Lindqvist; K Eberhardt; K Bendtzen; D Heinegård; T Saxne
Journal:  Ann Rheum Dis       Date:  2004-09-30       Impact factor: 19.103

10.  Autoantibodies against interleukin 1alpha in rheumatoid arthritis: association with long term radiographic outcome.

Authors:  N A Graudal; M Svenson; U Tarp; P Garred; A-G Jurik; K Bendtzen
Journal:  Ann Rheum Dis       Date:  2002-07       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.